Rapid antidepressant response to alprazolam in depressed patients with high catecholamine output and heterologous desensitization of platelet adenylate cyclase.
The present study examined the relationship between 24-hr urinary catecholamine (norepinephrine and epinephrine) output and measures of platelet adenylate cyclase (AC) activity in depressed patients (n = 17) and control subjects (n = 10). In both groups, significant inverse correlations were observed when 24-hr urinary catecholamine levels were examined in relation to measures of both receptor-mediated (prostaglandin D2 and alpha 2-adrenergic) and postreceptor-mediated (NaF) platelet AC enzyme activities, suggesting that circulating catecholamines may regulate platelet AC by heterologous (agonist-nonspecific) desensitization of the AC enzyme complex. Depressed patients who had favorable antidepressant responses to alprazolam had significantly higher pretreatment urinary catecholamine output and lower receptor-mediated platelet AC enzyme activities than control subjects, whereas the nonresponders did not. After 8 days of treatment with alprazolam, urinary catecholamine levels declined significantly. In responders, receptor-mediated measures of platelet AC activity increased significantly by day 8 to values comparable to those in control subjects; but similar changes were not observed in nonresponders. Prior to treatment, responders showed a strict linear relationship between receptor-mediated (prostaglandin D2) and postreceptor-mediated (NaF) stimulation of platelet AC activity through the stimulatory guanine nucleotide regulatory protein (Ns), whereas nonresponders did not. This suggests the presence of two distinct coupling interactions between platelet prostaglandin D2 receptors and the stimulatory guanine nucleotide regulatory protein in responders and nonresponders to the antidepressant effects of alprazolam prior to treatment. The authors propose that catecholamines, possibly acting through prostaglandins, may regulate platelet AC enzyme activity by heterologous desensitization occurring through postreceptor mechanisms.
Mooney
J J
JJ
Neuropsychopharmacology Laboratory, Massachusetts Mental Health Center, Boston 02115.
Schatzberg
A F
AF
Cole
J O
JO
Kizuka
P P
PP
Salomon
M
M
Lerbinger
J
J
Pappalardo
K M
KM
Gerson
B
B
Schildkraut
J J
JJ
D000262:Adenylyl Cyclases / Q000097:blood*; D000328:Adult; D000525:Alprazolam / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects* / Q000201:enzymology; D002395:Catecholamines / Q000652:urine*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000201:enzymology; D003907:Dexamethasone; D004837:Epinephrine / Q000652:urine; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D009638:Norepinephrine / Q000652:urine; D011581:Psychological Tests; D011941:Receptors, Adrenergic / Q000187:drug effects
D002395:Catecholamines; D011941:Receptors, Adrenergic; D003907:Dexamethasone; D000262:Adenylyl Cyclases; D006854:Hydrocortisone; D009638:Norepinephrine; D004837:Epinephrine; D000525:Alprazolam